Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Rare Tumour × Cisplatin × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 473 Squamous Cell Carcinoma of Head and Neck 235 Head and Neck Neoplasms 223 Lung Neoplasms 218 Uterine Cervical Neoplasms 154 Stomach Neoplasms 149 Esophageal Neoplasms 146 Nasopharyngeal Carcinoma 117 Urinary Bladder Neoplasms 100 Esophageal Squamous Cell Carcinoma 100 Neoplasms 99 Small Cell Lung Carcinoma 93 Breast Neoplasms 84 Ovarian Neoplasms 79 Neoplasm Metastasis 75 Carcinoma, Squamous Cell 72 Pancreatic Neoplasms 69 Cholangiocarcinoma 63 Biliary Tract Neoplasms 63 Mesothelioma, Malignant 54 Adenocarcinoma Of Esophagus 48 Oropharyngeal Neoplasms 46 Carcinoma 46 Recurrence 43 Carcinoma, Ovarian Epithelial 42 Parkinson Disease 4, Autosomal Dominant Lewy Body 41 Lymphoma 37 Adenocarcinoma of Lung 37 Gallbladder Neoplasms 35 Nasopharyngeal Neoplasms 34

Interventions

toripalimab 1 tislelizumab 1 sintilimab 1 pyrotinib 1 pembrolizumab 1 pamiparib 1 palbociclib 1 osimertinib 1 neratinib 1 erdafitinib 1 envafolimab 1 entrectinib 1 durvalumab 1 camrelizumab 1 atezolizumab 1 alectinib 1 Vinorelbine 1 Vemurafenib 1 Teniposide 1 Nivolumab 1 Irinotecan 1 Imatinib Mesylate 1 Gemcitabine 1 Fluorouracil 1 Epirubicin 1 Cisplatin 1 Albumin-Bound Paclitaxel 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting

Rare Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡